SMIM39: A Protein with Potential as A Drug Target Or Biomarker

Target Name: SMIM39

NCBI ID: G113523639

SMIM39

Other Name(s): SIM39_HUMAN | Small integral membrane protein 39 | small integral membrane protein 39

SMIM39: A Protein with Potential as A Drug Target Or Biomarker

SMIM39 (SIM39_HUMAN), also known as human simian myeloid-derived intracellular matrix (HSM-ICM), is a protein that is expressed in the human body and is derived from the simian myeloid lineage of mice. SMIM39 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, SMIM39 has potential as a drug target or biomarker for a variety of diseases.

SMIM39 is a member of the SIM complex, which is a family of proteins that are involved in the regulation of cell adhesion, migration, and invasion. The SIM complex includes a variety of different proteins, including SMIM1, SMIM2, and SMIM39, which are all involved in the intracellular matrix (ICM) of cells. SMIM39 is specifically characterized by its ability to interact with other proteins in the SIM complex, including SMIM1 and SMIM2.

SMIM39 has been shown to be involved in the regulation of cell adhesion and migration. For example, studies have shown that SMIM39 can interact with the protein E-cadherin, which is a transmembrane protein that is involved in cell-cell adhesion. By interacting with E-cadherin, SMIM39 can influence the formation and maintenance of tight junctions, which are specialized barriers that help to maintain the integrity of the intercellular space.

In addition to its role in cell adhesion and migration, SMIM39 has also been shown to be involved in the regulation of cell proliferation. Studies have shown that SMIM39 can interact with the protein p21, which is a tumor suppressor protein that is involved in the regulation of cell growth and division. By interacting with p21, SMIM39 can inhibit the activity of p21 and prevent it from inhibiting the growth and expansion of cancer cells.

SMIM39 has also been shown to be involved in the regulation of neurodegenerative diseases. For example, studies have shown that SMIM39 can interact with the protein tau, which is a protein that is involved in the regulation of cell division and growth in the brain. By interacting with tau, SMIM39 can influence the formation and stability of tau tangles, which are a hallmark of neurodegenerative diseases.

In addition to its potential role in neurodegenerative diseases, SMIM39 has also been shown to be involved in the regulation of autoimmune disorders. Studies have shown that SMIM39 can interact with the protein PDGF-R2, which is a protein that is involved in the regulation of cell growth and differentiation. By interacting with PDGF-R2, SMIM39 can influence the activity of PDGF-R2 and prevent it from promoting the growth and expansion of autoimmune cells.

SMIM39 is also a potential drug target for a variety of diseases. For example, studies have shown that SMIM39 can be targeted with small molecules, such as inhibitors of tyrosine kinase activity, which can inhibit the activity of SMIM39 and prevent it from interacting with other proteins in the SIM complex. Additionally, SMIM39 can be targeted with antibodies that recognize and target specific epitopes on the protein.

In conclusion, SMIM39 is a protein that is expressed in the human body and is derived from the simian myeloid lineage of mice. SMIM39 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, SMIM39 has potential as a drug target or biomarker for a variety of diseases. Further research is needed to fully understand the role of SMIM39 in the regulation of

Protein Name: Small Integral Membrane Protein 39

The "SMIM39 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMIM39 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets